Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics.
about
Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphomaCD30: from basic research to cancer therapySerious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies.Immunotherapies for Hodgkin's lymphoma.Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees.Drug development for recurrent and refractory classical Hodgkin lymphoma.Investigational antibody-drug conjugates for hematological malignancies.Targetable molecular pathways in classical Hodgkin's lymphoma.Brentuximab vedotin for the treatment of CD30+ lymphomas.Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma).CD30: an important new target in hematologic malignancies.Role of CD30 targeting in malignant lymphoma.Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma.CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma.Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.
P2860
Q24633761-8D4FB1F7-B1AF-4B2C-AB01-CE4D3715CDC6Q26859079-564C6ACB-2A9F-41B6-AA63-E80FA6BCD1EEQ34231085-738BA6B0-363A-4AF8-9981-EE58D52FFEF5Q34557179-B75F2436-A47D-4EBF-B4BE-C81B15EB741EQ37006427-1528DC85-DE0C-4C42-8484-B1158C69B5FFQ37420514-598612D8-BEC5-4C3C-B774-E4F1C4700897Q37448408-B3635E68-F758-4AC2-AF43-1C45CED7FF0DQ37818256-375FB379-BFC6-46E9-9848-B9189A6320D9Q37825891-0DD1E10D-B700-45FC-A76A-B5311BBBB20DQ37861212-5040E3DA-4563-4EAB-BEFF-F22FEAC23C5AQ37863688-EB1BAF0E-1DCE-4592-975D-CC5F086BFC92Q37880873-2D40AAB3-6993-45D6-9D28-445EA3D8F522Q38191191-5DA54E5E-3E6D-46F5-B2DA-4205BA6F117EQ38205923-8B948BD1-42A3-429A-B79E-0E4379A19BCAQ38950501-491FF422-BD6F-4249-9A07-82127DC21981Q42384513-1F78F02F-F9D9-4A02-A2EE-AFABDD5EDB28Q47102763-C216F092-4534-47AD-A136-509EDE861332
P2860
Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Signaling via the anti-CD30 mA ...... onventional chemotherapeutics.
@en
type
label
Signaling via the anti-CD30 mA ...... onventional chemotherapeutics.
@en
prefLabel
Signaling via the anti-CD30 mA ...... onventional chemotherapeutics.
@en
P2093
P2860
P356
P1433
P1476
Signaling via the anti-CD30 mA ...... onventional chemotherapeutics.
@en
P2093
Cerveny CG
Francisco JA
Hamblett KJ
McCormick RS
Petroziello JM
Westendorf LE
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403884
P577
2005-09-01T00:00:00Z
P5875
P6179
1027762268